Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 25,93 € (+109,96 %). La mediana es de 25,93 € (+109,96 %).
| Comprar |
13 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
MediWound: VALUE study for EscharEx as decisive near-term catalyst
MediWound presented its bromelain platform at the H.C. Wainwright conference, highlighting NexoBrid revenue potential and the upcoming VALUE phase III study for EscharEx as key drivers. The VALUE study (216 patients) includes an interim analysis at ~65% recruitment; various sample-size adjustments are possible, and topline data are expected about three months after the interim analysis. The company is expanding production capacity, expects European approval in mid‑2027, and points to commercial progress with NexoBrid as well as a BARDA-linked partnership with Vericel. » Más en de.investing.com
MediWound calls extraordinary general meeting for Feb. 19
MediWound has called an extraordinary general meeting for Feb. 19, 2026, and on Jan. 15, 2026 filed the related notice and a proxy statement with the SEC. Registered shareholders will receive voting materials and a proxy card. The filings give meeting details but do not disclose specific agenda items; the documents refer to existing registration statements on Forms S-8 and F-3. » Más en de.investing.com
MediWound: study shows NexoBrid removes over 90% of traumatic tattoos
A prospective study at Sheba Medical Center found that MediWound’s enzymatic preparation NexoBrid reduced the pigmented wound surface by an average of 92.5% in 15 patients (96% for abrasion injuries, 84% for blast injuries). The treatment was administered at the bedside under sedation within 24 hours and showed no treatment-related adverse events in early follow-up. MediWound recently raised around $30 million via a direct offering, received approval in Australia and is planning production and capacity expansions; one analyst raised the price target. » Más en de.investing.com
MediWound raises $30 million through registered direct placement
MediWound sold 1,734,105 ordinary shares at $17.30 per share in a registered direct placement, raising about $30 million. The transaction was led by a U.S. investment fund and other healthcare-focused investors; H.C. Wainwright & Co. served as sole placement agent. Net proceeds are intended to fund precommercial activities for EscharEx, expand manufacturing capacity and general corporate purposes. The company also reported TGA approval of NexoBrid in Australia and new study data on the importance of wound bed preparation. » Más en de.investing.com
MediWound presents growth plan and cites supply bottlenecks for NexoBrid
MediWound presented its growth strategy at the H.C. Wainwright conference, focusing on the phase-3 study of EscharEx and expansion of production capacity. The company reported supply chain problems with NexoBrid and plans a new manufacturing site in the US as well as an additional facility in Europe to address the shortages. Partnerships with BARDA and the DOD, cash of $33 million and a potential $30 million from warrants support the commercialization plans; a BARDA tender is expected in Q4 2025. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 3,15 M | 31,81 % |
| Beneficio bruto | 897,86 mil | 17,60 % |
| Beneficio neto | -5,29 M | 133,89 % |
| EBITDA | -7,2 M | 287,68 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 159,14 M € |
Número de acciones | 12,91 M |
Máximo/mínimo de 52 semanas | 20,10 € - 10,73 € |
| Dividendos | No |
Beta | 0,14 |
Ratio P/E | -7,45 |
Ratio PEG | 0,94 |
Ratio P/B | 5,53 |
Ratio P/S | 17,48 |
Perfil de la empresa
MediWound Ltd., una empresa biofarmacéutica, desarrolla, fabrica y comercializa soluciones bioterapéuticas novedosas para la reparación y regeneración de tejidos. Comercializa NexoBrid, un producto biofarmacéutico para la eliminación de escara, un tejido muerto o dañado, en adultos con quemaduras térmicas de espesor parcial profundo y total en centros de quemados y unidades de quemados de hospitales. La empresa también desarrolla EscharEx, que ha completado ensayos clínicos de fase II para el desbridamiento de heridas crónicas y otras heridas de difícil cicatrización; y MW005, que se encuentra en fase I/II para el tratamiento del carcinoma basocelular de bajo riesgo. MediWound Ltd. fue fundada en 2000 y tiene su sede central en Yavne, Israel.
| Nombre | MediWound |
| CEO | Ofer Gonen |
| Sede | Yavne,
hm Israel |
| Sitio web | |
| Sector | Consumo básico |
| Industria | Productos de cuidado personal |
| Salida a bolsa | 20/03/2014 |
| Empleados | 121 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | MDWD |
Frankfurt | M8W.F |